| [1] |
Lewis JS,Jordan VC. Selective estrogen receptor modulators( SERMs ): mechanisms of anticarcinogenesis and drug resistance[J].Mutat Res,2005,591(1-2): 247-263.
|
| [2] |
Riggins RB,Bouton AH,Liu MC,et al.Antiestrogens,aromatase inhibitors,and apoptosis in breast cancer[J]. Vitam Horm,2005,71: 201-237.
|
| [3] |
Sharma D, Saxena NK, Davidson NE, et al. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes[J]. Cancer Res, 2006, 66(12): 6370-6378.
|
| [4] |
Martens JW,Nimmrich I,Koenig T, et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer[J].Cancer Res,2005,65(10): 4101-4117.
|
| [5] |
Trimarchi MP, Mouangsavanh M, Huang TH. Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance[J]. Chin J Cancer,2011,30(11): 749-756.
|
| [6] |
Hostetter CL,Licata LA,Keen JC. Timing is everything: order of administration of 5-aza 2′ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity[J]. Cancer Lett,2009,275(2): 178-184.
|
| [7] |
Raha P, Thomas S, Munster PN. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance[J]. Epigenomics,2011,3(4): 451-470.
|
| [8] |
Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy [J]. Nature,2004,429(6990): 457-463.
|
| [9] |
Raaphorst FM,Meijer CJ,Fieret E,et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene[J]. Neoplasia, 2003,5(6): 481-488.
|
| [10] |
Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells[J]. Proc Natl Acad Sci U S A,2003,100(20): 11606-11611.
|
| [11] |
Hwang C, Giri VN, Wilkinson JC, et al. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor[J]. Breast Cancer Res Treat,2008,107(2): 235-242.
|
| [12] |
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method[J]. Methods,2001,25(4): 402-408.
|
| [13] |
Ring A, Dowsett M. Mechanisms of tamoxifen resistance[J].Endocr Relat Cancer,2004,11(4): 643-658.
|
| [14] |
Wei Y, Lai X, Yu S, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells[J]. Breast Cancer Res Treat,2014,147(2): 423-431.
|
| [15] |
Ward A, Shukla K, Balwierz A, et al. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer[J].J Pathol,2014,233(4): 368-379.
|
| [16] |
Oosterkamp HM, Hijmans EM, Brummelkamp TR, et al.USP9X downregulation renders breast cancer cells resistant to ramoxifen[J]. Cancer Res,2014,74(14): 3810-3820.
|
| [17] |
Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients [J]. Breast Cancer Res, 2005, 7 (3): R284-290.
|
| [18] |
Reijm EA, Jansen M, Ruigrok-Ritstier K, et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer[J].Breast Cancer Res Treat,2011,125(2): 387-394.
|
| [19] |
Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer[J].Cancer Res,2012,72(12): 3091-3104.
|
| [20] |
Zhang B,Liu XX,He JR,et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer [ J ].Carcinogenesis,2011,32(1): 2-9.
|
| [21] |
Jansen M, Reijm EA,Sieuwerts AM,et al. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer[J]. Breast Cancer Res Treat,2012,133(3): 937-947.
|
| [22] |
Hayden A, Johnson PW, Packham G, et al. Sadenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition[J]. Breast Cancer Res Treat,2011,127(1): 109-119.
|
| [23] |
Helin K, Dhanak D. Chromatin proteins and modifications as drug targets[J]. Nature,2013,502(7472): 480-488.
|